Jounce Therapeutics IPO Research Information

Jounce Therapeutics IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Jounce Therapeutics, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Jounce Therapeutics	JNCE - NASDAQ	$13.00-$15.00	$16.00	$18.00	6.365 million	1/27/2017
Underwriter(s): J.P. Morgan, Cowen and Company
Co-Manager(s): Wells Fargo Securities, Baird
Industry: Health Care
Filing(s): Filed 2016-12-30 Terms Added 2017-01-17

Jounce Therapeutics Quote & Chart - Click for current quote - JNCE

About Jounce Therapeutics (adapted from Jounce Therapeutics prospectus):
They are a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "JNCE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.